ntroduction: Moderate to severe atopic der-matitis (AD) is associated with a significant disease burden, impacting sleep, quality of life, and treat-ment needs. The aim of this study was to charac-terize disease burden and treatment patterns for adults with moderate to severe AD in three Euro-pean countries: France, Italy, and the UK. Methods: This retrospective analysis of adult patients with moderate to severe AD in Europe used medical records and physician/patient sur- vey data collected in August 2019 to April 2020. Demographic and baseline disease characteristics, information on current comorbidities, disease flares, and current and previous treatments were collected by the physician. Patient-perceived burden was assessed using patient-reported out-come (PRO) questionnaires, which were com- pleted on a voluntary basis and included the following instruments: Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), EuroQol five-dimensional (EQ-5D), and Work Productivity and Activity Impairment (WPAI). Disease severity was subjectively assessed by physicians and was based on their own defini-tion of the terms mild, moderate, and severe. Data were analyzed descriptively. Results: The physician-reported sample inclu-ded 912 patients with moderate to severe dis-ease from France (n = 314), Italy (n = 309), and the UK (n = 289); approximately 30% of patients provided PRO data. Across these countries, 22–41% of patients reported current